Detalhe da pesquisa
1.
Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
J Thromb Thrombolysis
; 44(1): 118-129, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28540468
2.
Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function.
Eur Heart J
; 39(47): 4208-4218, 2018 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329262
3.
Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.
Res Pract Thromb Haemost
; 4(4): 569-581, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32548555
4.
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.
Thromb Haemost
; 118(1): 174-181, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29304537
5.
Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate.
Res Pract Thromb Haemost
; 2(1): 77-84, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30046709
6.
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Thromb Res
; 162: 7-14, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29248859
7.
Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent.
TH Open
; 2(1): e1-e7, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31249922
8.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Thromb Haemost
; 117(10): 1944-1951, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28816341
9.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.
Thromb Haemost
; 117(10): 1944-1951, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30151820
10.
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Thromb Haemost
; 117(4): 809-815, 2017 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28180233
11.
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Thromb Haemost
; 117(12): 2406-2414, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29212128
12.
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Thromb Haemost
; 116(1): 155-61, 2016 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27010092
13.
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Thromb Haemost
; 116(4): 747-53, 2016 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27440518
14.
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Lancet Haematol
; 3(5): e228-36, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132697
15.
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Lancet Haematol
; 3(9): e437-45, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27570090